Trademark Overview
On Friday, January 3, 2025, a trademark application was filed for DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY with the United States Patent and Trademark Office. The USPTO has given the DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY trademark a serial number of 98935691. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Friday, June 27, 2025. This trademark is owned by Replimune Limited. The DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products,...
Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid